Worse COVID-19 patients got 400,000 IU of vitamin D, deaths cut in half

Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study

Nutrients 2021, 13(1), 219; https://doi.org/10.3390/nu13010219

For those with 3 or more major health problems
100% died if no vitamin D   but only 40% died if had gotten vitamin D

Vitamin D was give to those who had the worse prognosis200,000 IU on 2nd day in hospital + 200,000 IU on 3rd day in hospitalNote by Vitamin D Life: Better survival expected if1. Give it all on the first day in hospital - not wait for the 2nd and 3rd day* and, far better, give vitamin D on the first day of having symptoms1. Use a gut-firendly form of vitamin D if symptoms are so bad that a person is in hospitslVitamin D loading dose (stoss therapy) proven to improve health 1. 400,000 COVID deaths, 400,000 IUs of Vitamin D needed to prevent COVID death - Jan 2021 1. COVID-19 treated by Vitamin D - studies, reports, videos{include} 1. Mortality and Virus{category}Note: >70% of the trials using Vitamin D to fight COVID-19 are using at least 100,000 IU during the first week--- 1. Study was reported on* "Covid, with vitamin D the risk of death and hospitalization in intensive care decreased by 80% "

📄 Download the PDF from Vitamin D Life

📄 Charts in appendix

Little information is available on the beneficial effects of cholecalciferol treatment in comorbid patients hospitalized for COVID-19. The aim of this study was to retrospectively examine the clinical outcome of patients receiving in-hospital high-dose bolus cholecalciferol. Patients with a positive diagnosis of SARS-CoV-2 and overt COVID-19, hospitalized from 15 March to 20 April 2020, were considered. Based on clinical characteristics, they were supplemented (or not) with 400,000 IU bolus oral cholecalciferol (200,000 IU administered in two consecutive days) and the composite outcome (transfer to intensive care unit; ICU and/or death) was recorded.

Ninety-one patients (aged 74 ± 13 years) with COVID-19 were included in this retrospective study. Fifty (54.9%) patients presented with two or more comorbid diseases.

Based on the decision of the referring physician , 36 (39.6%) patients were treated with vitamin D.

Receiver operating characteristic curve analysis revealed a significant predictive power of the four variables:

• (a) low (<50 nmol/L) 25(OH) vitamin D levels,

• (b) current cigarette smoking,

• (c) elevated D-dimer levels

• (d) and the presence of comorbid diseases,

to explain the decision to administer vitamin D (area under the curve = 0.77, 95% CI: 0.67–0.87, p < 0.0001).

Over the follow-up period (14 ± 10 days), 27 (29.7%) patients were transferred to the ICU and 22 (24.2%) died (16 prior to ICU and six in ICU).

Overall, 43 (47.3%) patients experienced the combined endpoint of transfer to ICU and/or death. Logistic regression analyses revealed that the comorbidity burden significantly modified the effect of vitamin D treatment on the study outcome, both in crude (p = 0.033) and propensity score-adjusted analyses (p = 0.039), so the positive effect of high-dose cholecalciferol on the combined endpoint was significantly amplified with increasing comorbidity burden. This hypothesis-generating study warrants the formal evaluation (i.e., clinical trial) of the potential benefit that cholecalciferol can offer in these comorbid COVID-19 patients.

Clipped from PDF

"Overall, 43 (47.3%) patients experienced the combined endpoint of transfer to ICU or death . In a crude analysis, initially including comorbidity burden as a potential confounder, vitamin D treatment was observed to be associated with a 43% and 55% reduction, respectively, in the OR of the combined endpoint, but these effects did not attain statistical significance (Table 3)"

Summary: 55% less likely to die, but too few of people to be statistically significant

Title change made Feb 2020 caused the visitor count to reset.
There have actually been visitors to this page since it was originally made